Abstral is a sublingual (under the tongue) fentanyl tablet indicated for the management of breakthrough pain in patients with cancer. The drug is intended for individuals 18 years of age and older who are already receiving, and who are tolerant to, opioid therapy for their persistent baseline cancer pain.
Following its acquisition of Abstral in March 2013, Galena has made significant efforts to bring the product to market via prescription at all retail pharmacies nationwide. In a news release this morning, the company said it scaled its field commercial team, manufactured the drug for commercial sale, secured broad access and reimbursement support from commercial and federal health insurance entities, implemented a robust patient assistance program, and developed a broad product distribution network to ensure its availability.
“As an oncology company dedicated to improving patients’ lives, we are thrilled to introduce Abstral as our first commercial product and offer cancer patients relief from their breakthrough pain,” stated GALE CEO Mark J. Ahn. “We believe Abstral delivers best in class performance because it is simple to carry, simple to use, and requires no special handling or disposal. We have a commercial team of highly dedicated, patient-focused professionals with experience in both pain and oncology who have helped us reach this tremendous milestone for Galena. I look forward to reporting our continued progress later this year.”
Breakthrough cancer pain is a temporary pain (lasting roughly 30 minutes) that occurs either spontaneously or in relation to a specific predictable or unpredictable trigger, despite the patient having relatively stable and adequately controlled background pain.
Dissolved under the tongue, delivers pain relief in a matter of minutes and matches the duration of the entire pain episode.
For more information, visit www.galenabiopharma.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html
